
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc. demonstrated robust financial performance in the quarter ended June 30, 2025, with revenue increasing by 157% to $1.8 million, driven by strong demand for its LungFit PH system across domestic and international markets. The company achieved a milestone with positive gross profit of $0.2 million, a significant recovery from a gross loss of $0.3 million in the prior year, highlighting a turnaround in its growth trajectory. Additionally, the strategic national group purchasing agreement with Premier, Inc. enhances access to Beyond Air's innovative technology across over 4,350 hospitals and health systems, potentially fostering accelerated commercial adoption and broader market penetration.
Bears say
Beyond Air Inc. reported a net loss of $7.9 million for the latest period, indicating ongoing financial challenges despite a reduction in gross loss and operating expenses compared to the previous year. The company’s research and development expenses decreased substantially to $2.5 million, but the net cash burn of $4.7 million raises concerns about its financial sustainability. Additionally, the potential adverse effects of Nitric Oxide on cellular respiration within the tumor microenvironment may complicate the development of its therapies, further contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares